{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:23:07Z","timestamp":1776450187950,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Vifor Pharma Italia Srl"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s12325-019-01089-z","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T15:02:47Z","timestamp":1567695767000},"page":"3253-3264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-0591","authenticated-orcid":false,"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Ortalda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Biasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943.","journal-title":"PLoS One"},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000486968","volume":"47","author":"JB Wish","year":"2018","unstructured":"Wish JB, Aronoff GR, Bacon BR, et al. Positive iron balance in chronic kidney disease: how much is too much and howto tell? Am J Nephrol. 2018;47:72\u201383.","journal-title":"Am J Nephrol"},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1185\/03007990903512461","volume":"26","author":"IC Macdougall","year":"2010","unstructured":"Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin. 2010;26:473\u201382.","journal-title":"Curr Med Res Opin"},{"key":"1089_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/ndt\/gft062","volume":"28","author":"GR Bailie","year":"2013","unstructured":"Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28:2570\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2012.76","volume":"82","author":"DW Coyne","year":"2012","unstructured":"Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82:235\u201341.","journal-title":"Kidney Int"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019\u201332.","journal-title":"N Engl J Med"},{"issue":"11","key":"1089_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671\u20136.","journal-title":"Haematologica"},{"issue":"1","key":"1089_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","volume":"2016","author":"M Auerbach","year":"2016","unstructured":"Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):57\u201366.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt K-U, Gaillard C, Van Wyck D, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltoseversus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"DB Van Wyck","year":"2005","unstructured":"Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846\u201356.","journal-title":"Kidney Int"},{"issue":"5","key":"1089_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000096174","volume":"26","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445\u201354 (Epub 2006 Oct 11).","journal-title":"Am J Nephrol"},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","volume":"25","author":"A Covic","year":"2010","unstructured":"Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25:2722\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1089_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/ndt\/gfs528","volume":"28","author":"C Charytan","year":"2013","unstructured":"Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013;28(4):953\u201364.","journal-title":"Nephrol Dial Transplant"},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12882-018-1045-8","volume":"19","author":"JMG Hofman","year":"2018","unstructured":"Hofman JMG, Eisenga MF, Diepenbroek A, et al. Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients. BMC Nephrology. 2018;19:242.","journal-title":"BMC Nephrology"},{"issue":"4","key":"1089_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000493551","volume":"48","author":"IC Macdougall","year":"2018","unstructured":"Macdougall IC, White C, Anker SD, et al. Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. Am J Nephrol. 2018;48(4):260\u20138.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1089_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447\u201358.","journal-title":"N Engl J Med"},{"key":"1089_CR18","volume-title":"Encyclopedia of behavioral medicine","author":"A Duenas","year":"2013","unstructured":"Duenas A. Cost-minimization analysis. In: Gellman MD, Turner JR, editors. Encyclopedia of behavioral medicine. New York: Springer; 2013."},{"issue":"3","key":"1089_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","volume":"6","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant? JACC Heart Fail. 2018;6(3):201\u20138.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"1089_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MAJ.0b013e31827981be","volume":"347","author":"JM Chang","year":"2014","unstructured":"Chang JM, Chen SC, Huang JC, Su HM, Chen HC. Anemia and left ventricular hypertrophy with renal function decline and cardiovascular events in chronic kidney disease. Am J Med Sci. 2014;347(3):183\u20139.","journal-title":"Am J Med Sci"},{"issue":"Suppl","key":"1089_CR21","first-page":"S59","volume":"16","author":"RE Smith","year":"2010","unstructured":"Smith RE. The clinical and economic burden of anemia. Am J Manag Care. 2010;16(Suppl):S59\u201366.","journal-title":"Am J Manag Care."},{"issue":"2","key":"1089_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/ndt\/gfs487","volume":"28","author":"G Wong","year":"2013","unstructured":"Wong G, Howard K, Hodson E, Irving M, Craig JC. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrol Dial Transplant. 2013;28(2):413\u201320.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"1089_CR23","doi-asserted-by":"publisher","first-page":"i457","DOI":"10.1093\/ndt\/gfy104.SP335","volume":"33","author":"R Minutolo","year":"2018","unstructured":"Minutolo R, Liberti ME, Berto P. Economics of intravenous ferric carboxymaltose for treatment of iron deficient anaemia in patients with non-dialysis chronic kidney disease: a pilot study in Italy. Nephrol Dial Transplant. 2018;33(Suppl 1):i457.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1089_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12882-019-1263-8","volume":"20","author":"M Diebold","year":"2019","unstructured":"Diebold M, Kistler AD. Evaluation of iron stores in hemodialysis patients on maintenance ferric carboxymaltose dosing. BMC Nephrol. 2019;20(1):76.","journal-title":"BMC Nephrol."},{"issue":"1","key":"1089_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2016.01.011","volume":"68","author":"R Minutolo","year":"2016","unstructured":"Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, et al. Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients. Am J Kidney Dis. 2016;68(1):170\u20132.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1089_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfu345","volume":"30","author":"V Panichi","year":"2015","unstructured":"Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, et al. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant. 2015;30(4):682\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"1089_CR27","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med."},{"issue":"3","key":"1089_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ejhf.229","volume":"17","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, L\u00fcscher T, et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17(3):329\u201339.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1089_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657\u201368.","journal-title":"Eur Heart J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01089-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01089-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01089-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:28:07Z","timestamp":1599175687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01089-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01089-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}